Literature DB >> 17704318

Stability of linear and macrocyclic gadolinium based contrast agents.

H Schmitt-Willich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17704318     DOI： 10.1259/bjr/17326033

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


× No keyword cloud information.
  23 in total

1.  Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?

Authors:  Sameh K Morcos
Journal:  Eur Radiol       Date:  2010-09-17       Impact factor: 5.315

2.  Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data.

Authors:  Sameh K Morcos; John Haylor
Journal:  World J Radiol       Date:  2010-11-28

3.  Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.

Authors:  Ti-Yung Tseng; Jeng-Hwei Tseng; Bing-Shen Huang; Shen-Yen Lin; Chun-Bing Chen; Yi-Wen Fang; Gigin Lin; Ying-Chieh Lai
Journal:  Abdom Radiol (NY)       Date:  2021-03-20

4.  Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model.

Authors:  Sohi Bae; Ho-Joon Lee; Kyunghwa Han; Yae-Won Park; Yoon Seong Choi; Sung Soo Ahn; Jinna Kim; Seung-Koo Lee
Journal:  Eur Radiol       Date:  2017-01-12       Impact factor: 5.315

Review 5.  X-ray-computed tomography contrast agents.

Authors:  Hrvoje Lusic; Mark W Grinstaff
Journal:  Chem Rev       Date:  2012-12-05       Impact factor: 60.622

6.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Authors:  Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  Eur Radiol       Date:  2008-06-11       Impact factor: 5.315

7.  Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial.

Authors:  Bernd Tombach; Klaus Bohndorf; Wolfgang Brodtrager; Claus D Claussen; Christoph Düber; Michael Galanski; Eckhardt Grabbe; Giacomo Gortenuti; Michael Kuhn; Walter Gross-Fengels; Renate Hammerstingl; Brigitte Happel; Gertraud Heinz-Peer; Gregor Jung; Thomas Kittner; Roberto Lagalla; Philipp Lengsfeld; Reinhard Loose; Raymond H G Oyen; Pietro Pavlica; Christiane Pering; Roberto Pozzi-Mucelli; Thorsten Persigehl; Peter Reimer; Nomdo S Renken; Götz M Richter; Ernst J Rummeny; Fritz Schäfer; Malgorzata Szczerbo-Trojanowska; Andrzej Urbanik; Thomas J Vogl; Paul Hajek
Journal:  Eur Radiol       Date:  2008-07-08       Impact factor: 5.315

8.  Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles.

Authors:  E A Wallnöfer; G C Thurner; C Kremser; H Talasz; M M Stollenwerk; A Helbok; N Klammsteiner; K Albrecht-Schgoer; H Dietrich; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2020-10-11       Impact factor: 4.304

9.  Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.

Authors:  E Kanal; T J Patton; I Krefting; C Wang
Journal:  AJNR Am J Neuroradiol       Date:  2020-02-27       Impact factor: 3.825

Review 10.  National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain.

Authors:  Ashkan A Malayeri; Kristina M Brooks; L Henry Bryant; Robert Evers; Parag Kumar; Daniel S Reich; David A Bluemke
Journal:  J Am Coll Radiol       Date:  2016-01-23       Impact factor: 5.532
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.